| Index | — | P/E | — | EPS (ttm) | -3.11 | Insider Own | 1.62% | Shs Outstand | 68.85M | Perf Week | 3.70% |
| Market Cap | 6.37B | Forward P/E | — | EPS next Y | -0.65 | Insider Trans | -26.98% | Shs Float | 56.04M | Perf Month | -0.90% |
| Enterprise Value | 6.05B | PEG | — | EPS next Q | -0.71 | Short Float | 19.64% | Perf Quarter | -9.93% | ||
| Income | -206.00M | P/S | 26.67 | EPS this Y | — | Short Ratio | 16.39 | Perf Half Y | 13.15% | ||
| Sales | 239.00M | P/B | 29.37 | EPS next Y | — | ROA | -46.96% | Short Interest | 11.00M | Perf YTD | -13.52% |
| Book/sh | 3.15 | P/C | 19.26 | EPS next 5Y | — | ROE | -80.48% | 52W High | 122.20 -24.25% | Perf Year | -18.72% |
| Cash/sh | 4.81 | P/FCF | — | EPS past 3/5Y | — | ROIC | -63.82% | 52W Low | 74.50 24.26% | Perf 3Y | 318.87% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 99.30% — | Gross Margin | 89.00% | Volatility | 2.91% 3.46% | Perf 5Y | 743.08% |
| Dividend TTM | — | EV/Sales | 25.30 | EPS Y/Y TTM | — | Oper. Margin | -83.62% | ATR (14) | 3.27 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 3.20 | Sales Y/Y TTM | 52.23% | Profit Margin | -85.59% | RSI (14) | 50.25 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 3.45 | EPS Q/Q | 2.67% | SMA20 | 3.09% | Beta | 2.15 | Target Price | 144.43 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | 44.90% | SMA50 | -4.74% | Rel Volume | 0.65 | Prev Close | 93.07 |
| Employees | 414 | LT Debt/Eq | 0.01 | Earnings | Nov 03 | SMA200 | -4.66% | Avg Volume | 654.12K | Price | 92.57 |
| IPO Date | Oct 09, 2017 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 9.57% 5.32% | Net Debt/EBITDA | — | Volume | 427,713 | Change | -0.54% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-12-26 | Reiterated | HC Wainwright & Co. | Buy | $125 → $130 |
| Oct-08-26 | Reiterated | RBC Capital | Outperform | $141 → $159 |
| Aug-28-26 | Initiated | Deutsche Bank | Hold | $120 |
| Aug-05-26 | Reiterated | Canaccord Genuity | Buy | $151 → $154 |
| Aug-05-26 | Reiterated | National Bank | $160 | |
| Jul-07-26 | Reiterated | RBC Capital | Outperform | $145 → $141 |
| Jun-16-26 | Reiterated | Canaccord Genuity | Buy | $143 → $151 |
| Jun-15-26 | Reiterated | Stifel Nicolaus | Buy | $131 → $133 |
| Jun-15-26 | Reiterated | Wells Fargo | Overweight | $143 → $155 |
| May-07-26 | Reiterated | Canaccord Genuity | Buy | $141 → $143 |
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 239 | 190 | 130 | 77 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 26 | 19 | 13 | 9 | — | — | — | — | — | |
| Gross Profit | 213 | 170 | 117 | 68 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 240 | 195 | 144 | 118 | — | — | — | — | — | |
| Research and Development | 173 | 167 | 238 | 135 | — | — | — | — | — | |
| Other Operating Expense | 1 | 0 | 0 | -1 | — | — | — | — | — | |
| Operating Income | -201 | -192 | -266 | -184 | — | — | — | — | — | |
| Interest Expense | 20 | 21 | 21 | 14 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 15 | 17 | 26 | 14 | — | — | — | — | — | |
| Net Income Before Taxes | -205 | -196 | -260 | -184 | — | — | — | — | — | |
| Income Taxes | 1 | 0 | 0 | 1 | — | — | — | — | — | |
| Consolidated Net Income | -206 | -197 | -261 | -185 | — | — | — | — | — | |
| Net Income From Continuing Operations | -206 | -197 | -261 | -185 | — | — | — | — | — | |
| Net Income | -206 | -197 | -261 | -185 | — | — | — | — | — | |
| EPS (Recurring) | -3.11 | -3.11 | -4.34 | -3.20 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.11 | -3.11 | -4.34 | -3.20 | — | — | — | — | — | |
| EPS (Diluted) | -3.11 | -3.11 | -4.34 | -3.20 | — | — | — | — | — | |
| EBITDA | -185 | -174 | -238 | -168 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 26.73 | 36.62 | 26.27 | 34.63 | — | — | — | — | — | |
| Gross Margin | 89.12 | 89.47 | 90.00 | 88.31 | — | — | — | — | — | |
| Operating Margin | -84.10 | -101.05 | -204.62 | -238.96 | — | — | — | — | — | |
| Net Margin | -86.19 | -103.68 | -200.77 | -240.26 | — | — | — | — | — | |
| Shares Outstanding | 69 | 65 | 61 | 58 | — | — | — | — | — | |
| Market Capitalization | 6,387 | 6,958 | 3,415 | 2,666 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Meeker David P | President and CEO | Sep 14 '26 | Sale | 102.67 | 50,000 | 5,133,442 | 239,258 | Sep 14 |
| Meeker David P | President and CEO | Sep 14 '26 | Option Exercise | 6.05 | 50,000 | 302,500 | 289,258 | Sep 14 |
| Smith Hunter C | Chief Financial Officer | Aug 31 '26 | Sale | 105.46 | 62,774 | 6,619,913 | 114,024 | Sep 01 |
| Smith Hunter C | Chief Financial Officer | Aug 31 '26 | Option Exercise | 25.79 | 57,187 | 1,474,853 | 176,798 | Sep 01 |
| Shulman Joseph | Chief Technical Officer | Aug 13 '26 | Sale | 119.75 | 5,079 | 608,210 | 15,915 | Aug 17 |
| Garfield Alastair | Chief Scientific Officer | Aug 13 '26 | Sale | 117.57 | 7,763 | 912,703 | 2,295 | Aug 17 |
| Shulman Joseph | Chief Technical Officer | Aug 13 '26 | Option Exercise | 6.80 | 2,024 | 13,763 | 20,994 | Aug 17 |
| Lee Jennifer Kayden | EVP, Head of North America | Aug 13 '26 | Option Exercise | 17.62 | 56,601 | 997,037 | 75,834 | Aug 14 |
| Lee Jennifer Kayden | EVP, Head of North America | Aug 13 '26 | Sale | 117.38 | 75,834 | 8,901,531 | 0 | Aug 14 |
| Mazabraud Yann | EVP, Head of International | Aug 12 '26 | Sale | 116.15 | 57,000 | 6,620,576 | 55,655 | Aug 14 |
| Mazabraud Yann | EVP, Head of International | Aug 12 '26 | Option Exercise | 6.80 | 46,625 | 317,050 | 112,655 | Aug 14 |
| Garfield Alastair | Chief Scientific Officer | Jul 01 '26 | Option Exercise | 0.00 | 4,445 | 0 | 12,208 | Jul 02 |
| Arbuckle Stuart A | Director | Jun 23 '26 | Option Exercise | 0.00 | 4,712 | 0 | 11,712 | Jun 25 |
| MCGIRR DAVID W J | Director | Jun 23 '26 | Option Exercise | 0.00 | 4,712 | 0 | 11,712 | Jun 25 |
| GOOD JENNIFER L | Director | Jun 23 '26 | Option Exercise | 0.00 | 4,712 | 0 | 11,712 | Jun 25 |